دورية أكاديمية
أعرض في EDS

Therapeutic activity of sarpogrelate and dopamine D 2 receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes.

التفاصيل البيبلوغرافية
العنوان: Therapeutic activity of sarpogrelate and dopamine D 2 receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes.
المؤلفون: Fouad Shalaby MA; Pharmaceutical Sciences Department, Pharmacy Programme, Batterjee Medical College, 21442, Jeddah, Saudi Arabia, KSA. Mafrec10@yahoo.com., Abd El Latif HA; Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt., El Yamani M; Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt., Galal MA; Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt., Kamal S; Pharmacology Department, National Organization for Drug Control and Research, Giza, Egypt., Sindi I; Research Unit, Batterjee Medical College, KSA, Jeddah, Saudi Arabia., Masaood R; Pharmaceutical Sciences Department, Pharmacy Programme, Batterjee Medical College, 21442, Jeddah, Saudi Arabia, KSA.
المصدر: BMC pharmacology & toxicology [BMC Pharmacol Toxicol] 2021 Oct 26; Vol. 22 (1), pp. 64. Date of Electronic Publication: 2021 Oct 26.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101590449 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-6511 (Electronic) Linking ISSN: 20506511 NLM ISO Abbreviation: BMC Pharmacol Toxicol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central
مواضيع طبية MeSH: Bromocriptine/*therapeutic use , Cabergoline/*therapeutic use , Diabetes Mellitus, Experimental/*drug therapy , Diabetic Nephropathies/*drug therapy , Dopamine Agonists/*therapeutic use , Myocardial Infarction/*drug therapy , Serotonin 5-HT2 Receptor Antagonists/*therapeutic use , Succinates/*therapeutic use, Animals ; Blood Glucose/drug effects ; Bromocriptine/pharmacology ; Cabergoline/pharmacology ; Diabetes Mellitus, Experimental/blood ; Diabetes Mellitus, Experimental/pathology ; Diabetic Nephropathies/blood ; Diabetic Nephropathies/pathology ; Dopamine Agonists/pharmacology ; Drug Therapy, Combination ; Isoenzymes/blood ; Kidney/drug effects ; Kidney/pathology ; L-Lactate Dehydrogenase/blood ; Male ; Myocardial Infarction/blood ; Myocardial Infarction/pathology ; Myocardium/pathology ; Rats, Wistar ; Serotonin 5-HT2 Receptor Antagonists/pharmacology ; Succinates/pharmacology ; Troponin I/blood ; Tumor Necrosis Factor-alpha/blood ; Rats
مستخلص: Background: Dopamine D 2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia. An affiliation was found between the initiation of myocardial injury ailment and long term treatment with dopamine D 2 agonist drugs identified with the partial activation of 5-hydroxytryptamine receptor 2 A (5-HT2A). The investigation aimed to examine the activity of sarpogrelate (a 5-HT2A receptor blocker) in reducing myocardial injury prompted by extended haul utilisation of D 2 receptor agonists in rats with alloxan-induced diabetes.
Methods: Both bromocriptine and cabergoline were managed independently and combined with sarpogrelate for about a month in diabetic nephropathy rats. Both tail-cuff blood pressure and the BGL were recorded weekly. For all animals, the kidney hypertrophy index, serum creatinine, blood urea nitrogen, alanine transaminase, and aspartate transaminase levels were measured after one month of treatment. The severity of the cardiac injury was assessed by the estimation of lactate dehydrogenase-1 (LDH-1), cardiac troponin I, and tumor necrosis factor alpha 1 (TNF1). The triphenyltetrazolium chloride (TTC) staining method was used to determine the experimental myocardial infarction (MI) size.
Results: Bromocriptine and cabergoline created a significant reduction in BGL, BP, and kidney hypertrophy index in diabetic nephropathy rats. Administration of bromocriptine and cabergoline, alone, or in combination with sarpogrelate fundamentally diminished the blood concentrations of alkaline phosphatase (ALP), Aspartate aminotransferase (AST), urea, and creatinine. Bromocriptine and cabergoline alone showed a noteworthy increase in the LDH-1, Troponin I, and TNF1 levels in the serum (p < 0.05). Paradoxically, utilising bromocriptine or cabergoline with sarpogrelate treatment altogether decreased the levels of the myocardial biomarkers in the serum. A mix of bromocriptine or cabergoline with sarpogrelate diminished the level of the myocardial infarct size in the heart assessed through the TTC staining method.
Conclusions: The examination demonstrated that the combined use of sarpogrelate with bromocriptine or cabergoline decreased the potential adverse effects of these two drugs on the myocardial tissues.
(© 2021. The Author(s).)
References: Diabetes Care. 2011 Apr;34(4):789-94. (PMID: 21447659)
Kidney Int. 1996 Oct;50(4):1101-9. (PMID: 8887266)
Rev Neurol (Paris). 2004 Sep;160(8-9):862-70. (PMID: 15454880)
J Pharmacol Exp Ther. 2011 Jul;338(1):381-91. (PMID: 21518772)
J Clin Pathol. 1954 Nov;7(4):322-6. (PMID: 13286357)
PLoS One. 2016 Apr 20;11(4):e0153965. (PMID: 27097221)
Horm Res. 2004;62(2):55-9. (PMID: 15205563)
Expert Opin Pharmacother. 2010 Feb;11(2):269-79. (PMID: 20030567)
Arch Endocrinol Metab. 2016 Oct;60(5):443-449. (PMID: 27812607)
J Heart Valve Dis. 2014 Mar;23(2):246-52. (PMID: 25076559)
Clin Sci (Lond). 2007 Jun;112(12):583-97. (PMID: 17492945)
Fundam Clin Pharmacol. 1998;12(6):599-606. (PMID: 9917201)
Mov Disord. 2009 Feb 15;24(3):344-9. (PMID: 18989898)
Ann Intern Med. 1986 Aug;105(2):238-53. (PMID: 3524338)
ILAR J. 2002;43(4):244-58. (PMID: 12391400)
JCI Insight. 2016 Jun 2;1(8):. (PMID: 27358912)
Biotechnol Appl Biochem. 2009 Mar;52(Pt 3):227-32. (PMID: 18588510)
J Am Soc Nephrol. 2003 Aug;14(8 Suppl 3):S250-3. (PMID: 12874441)
Eur J Endocrinol. 2008 Oct;159(4):R11-4. (PMID: 18625690)
J Cardiovasc Pharmacol Ther. 2002 Jan;7(1):53-9. (PMID: 12000979)
Kidney Int. 2004 Aug;66(2):633-40. (PMID: 15253716)
Anat Rec A Discov Mol Cell Evol Biol. 2004 Jul;279(1):685-91. (PMID: 15224410)
Am J Ther. 1998 Mar;5(2):81-8. (PMID: 10099042)
Ann N Y Acad Sci. 2005 Dec;1066:136-51. (PMID: 16533924)
Br J Pharmacol. 2015 Jul;172(14):3461-71. (PMID: 26114403)
Indian J Endocrinol Metab. 2011 Jul;15(Suppl 1):S17-24. (PMID: 21847449)
Biomed Res Int. 2013;2013:104059. (PMID: 23984312)
Am Heart J. 1981 May;101(5):593-600. (PMID: 6164281)
Cardiovasc Drug Rev. 2004 Spring;22(1):27-54. (PMID: 14978517)
Hypertension. 1986 Apr;8(4):298-302. (PMID: 2870024)
J Mol Cell Cardiol. 2004 Dec;37(6):1219-23. (PMID: 15572052)
Cardiovasc Psychiatry Neurol. 2009;2009:475108. (PMID: 20029624)
Am J Pathol. 1963 Apr;42:379-405. (PMID: 13937023)
Hypertension. 1996 Dec;28(6):1064-9. (PMID: 8952597)
J Endocrinol. 1999 Aug;162(2):237-42. (PMID: 10425461)
Clin Cardiol. 2002 Jan;25(1):28-32. (PMID: 11808836)
فهرسة مساهمة: Keywords: Cardiovascular; Diabetic nephropathy; Dopamine receptors; Myocardial injury; TNFα1
المشرفين على المادة: 0 (Blood Glucose)
0 (Dopamine Agonists)
0 (Isoenzymes)
0 (Serotonin 5-HT2 Receptor Antagonists)
0 (Succinates)
0 (Troponin I)
0 (Tumor Necrosis Factor-alpha)
19P708E787 (sarpogrelate)
3A64E3G5ZO (Bromocriptine)
EC 1.1.1.27 (L-Lactate Dehydrogenase)
EC 1.1.1.27.- (lactate dehydrogenase 1)
LL60K9J05T (Cabergoline)
تواريخ الأحداث: Date Created: 20211027 Date Completed: 20220304 Latest Revision: 20240226
رمز التحديث: 20240226
مُعرف محوري في PubMed: PMC8547108
DOI: 10.1186/s40360-021-00526-6
PMID: 34702339
قاعدة البيانات: MEDLINE
الوصف
تدمد:2050-6511
DOI:10.1186/s40360-021-00526-6